PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
439.10%
EBIT growth of 439.10% while Healthcare median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
10.94%
Operating income growth of 10.94% while Healthcare median is zero. Walter Schloss might see a modest advantage that can expand.
11.95%
Net income growth of 11.95% while Healthcare median is zero. Walter Schloss might see potential if moderate gains can keep rising.
11.92%
EPS growth of 11.92% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
11.92%
Diluted EPS growth of 11.92% while Healthcare median is zero. Walter Schloss might see a slight edge that could improve over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
61.50%
OCF growth of 61.50% while Healthcare is zero. Walter Schloss might see a modest positive difference, which can compound over time.
61.50%
FCF growth of 61.50% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.75%
Negative 10Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-26.75%
Negative 5Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-12.80%
Negative 3Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
-1.77%
Negative 10Y net income/share CAGR vs. Healthcare median of 17.97%. Seth Klarman might see a fundamental problem if peers maintain growth.
-1.77%
Negative 5Y CAGR while Healthcare median is 13.84%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-83.78%
Negative 3Y CAGR while Healthcare median is 2.91%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
-414.12%
Negative 10Y equity/share growth while Healthcare median is 0.00%. Seth Klarman would see a firm-specific weakness if peers still expand equity.
-414.12%
Negative 5Y equity/share growth while Healthcare median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-184.96%
Negative 3Y equity/share growth while Healthcare median is 0.00%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.90%
Negative BV/share change while Healthcare median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-100.00%
Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
-7.50%
SG&A decline while Healthcare grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.